Centessa Pharmaceuticals (CNTA) EBT (2020 - 2026)
Centessa Pharmaceuticals (CNTA) reported EBT of -$78.4 million for Q1 2026, down 216.88% year-over-year from $67.1 million in Q1 2025, and down 17.55% on a QoQ basis from -$66.7 million in Q4 2025.
Centessa Pharmaceuticals (CNTA) has 7 years of EBT data on file, last reported at -$78.4 million in Q1 2026.
- Quarterly EBT fell 216.88% year-over-year to -$78.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$249.4 million (down 13.3% YoY) and the FY2025 annual result came in at -$195.7 million, up 15.97% from the prior year.
- EBT eased to -$78.4 million in Q1 2026 per CNTA's latest filing, from -$66.7 million in the prior quarter.
- Across five years, EBT topped out at -$24.7 million in Q1 2025 and bottomed at -$110.3 million in Q4 2024.
- The 5-year median for EBT is -$49.6 million (2025), against an average of -$52.9 million.
- The widest annual swing landed in 2022, when EBT surged 77.2%; it then sank 216.88% in 2026.
- Tracing CNTA's EBT over 5 years: stood at -$43.8 million in 2022, then advanced by 18.58% to -$35.7 million in 2023, then slumped by 208.97% to -$110.3 million in 2024, then jumped by 39.53% to -$66.7 million in 2025, then dropped by 17.55% to -$78.4 million in 2026.
- Per Business Quant, the three latest CNTA EBT figures stand at -$78.4 million (Q1 2026), -$66.7 million (Q4 2025), and -$54.7 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -2.99 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -19.60 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -15.31 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.25 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -3.18 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 831.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 221.65 Mn |
| 10 | Centessa Pharmaceuticals | 6.12 Bn | 6.12 Bn | - | -78.39 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -78.39 Mn |
| Dec 31, 2025 | -66.69 Mn |
| Sep 30, 2025 | -54.73 Mn |
| Jun 30, 2025 | -49.57 Mn |
| Mar 31, 2025 | -24.74 Mn |
| Dec 31, 2024 | -110.28 Mn |
| Sep 30, 2024 | -41.96 Mn |
| Jun 30, 2024 | -43.11 Mn |
| Mar 31, 2024 | -37.57 Mn |
| Dec 31, 2023 | -35.69 Mn |
| Sep 30, 2023 | -41.47 Mn |
| Jun 30, 2023 | -48.94 Mn |
| Mar 31, 2023 | -50.04 Mn |
| Dec 31, 2022 | -43.84 Mn |
| Sep 30, 2022 | -54.02 Mn |
| Jun 30, 2022 | -64.68 Mn |
| Mar 31, 2022 | -54.42 Mn |
| Dec 31, 2021 | -60.66 Mn |
| Sep 30, 2021 | -40.16 Mn |
| Jun 30, 2021 | -41.45 Mn |
| Mar 31, 2021 | -238.69 Mn |
| Dec 31, 2020 | -3.02 Mn |
| Sep 30, 2020 | -2.14 Mn |
| Jun 30, 2020 | -2.15 Mn |